Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023".

Saved in:
Bibliographic Details
Title: Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023".
Authors: Tomeczkowski J; Institute for Evidence-Based Positioning in the Healthcare Sector, Bonn, Germany. j.tomeczkowski@dietrich.healthcare., Leverkus F; Evidence-Generating Data Evaluation, Berlin, Germany., Bussilliat P; Vfa, Berlin, Germany., Osowski U; Merck Healthcare GmbH Germany, Weiterstadt, Germany., Herrmann KH; Pharming, Ottobrunn, Germany., Eichinger B; Novartis Pharma GmbH, Nuremberg, Germany., Heidbrede T; UCB BioSciences, Monheim, Germany., Schmitter S; Pfizer Pharma GmbH, Berlin, Germany., Dietrich ES; Institute for Evidence-Based Positioning in the Healthcare Sector, Bonn, Germany., Dintsios CM; Institute for Health Services Research and Health Economics, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany., Bluhmki T; Bristol-Myers Squibb, Munich, Germany.
Source: Advances in therapy [Adv Ther] 2025 Aug; Vol. 42 (8), pp. 4096-4101. Date of Electronic Publication: 2025 Jun 20.
Publication Type: Letter
Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1865-8652
DOI:10.1007/s12325-025-03269-6